SCHEMBL10330632

SCHEMBL10330632

CN1CCC(c2nc(Cl)nc3ccccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTR2A P28223 1/20 0.45
HTR3A P46098 4/20 0.43
HTR3B O95264 3/20 0.43
HTR3E A5X5Y0 2/20 0.43
HTR3D Q70Z44 2/20 0.43
HTR3C Q8WXA8 2/20 0.43
NCF1 P14598 1/20 0.43
HRH4 Q9H3N8 3/20 0.41
KMT2A Q03164 1/20 0.40
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12410052 0.86 L3MBTL1 (0.57) TDP1L3MBTL1POLBMAPK1SMN1; SMN2
SCHEMBL30249575 0.86 L3MBTL1 (0.57) TDP1L3MBTL1POLBMAPK1SMN1; SMN2
SCHEMBL30013732 0.81 TDP1 (0.69) TDP1L3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL2534009 0.81 TDP1 (0.69) TDP1L3MBTL1KMT2AKDM4EALDH1A1
SCHEMBL28915370 0.77 GBA1 (0.43) TDP1L3MBTL1POLBTSHRMAPK1
SCHEMBL6337326 0.77 HTR3A (0.43) POLBTSHRMAPK1SMN1; SMN2HTR2A
SCHEMBL23261502 0.76 EHMT2 (0.62) L3MBTL1TSHRMAPK1SMN1; SMN2KMT2A
SCHEMBL11740420 0.73 TDP1 (0.44) TDP1L3MBTL1HTR2AHTR3AKMT2A
SCHEMBL5320912 0.73 HTR3B (0.69) TSHRMAPK1SMN1; SMN2HTR3AHTR3B
SCHEMBL5785756 0.72 POLB (0.48) L3MBTL1POLBTSHRMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754092-B2 Inhibitors of the hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2014-06-17 US disclosed
US-8754092-B2 Inhibitors of the hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2014-06-17 US disclosed
EP-2527330-A1 Inhibitors of the hedgehog pathway Exelixis, Inc. (US) 2012-11-28 EP disclosed
US-20120245139-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS PATENT COMPANY LLC (US) 2012-09-27 US disclosed
US-20120245139-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS PATENT COMPANY LLC (US) 2012-09-27 US disclosed
US-8222263-B2 Inhibitors of hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2012-07-17 US disclosed
US-8222263-B2 Inhibitors of hedgehog pathway EXELIXIS PATENT COMPANY LLC (US) 2012-07-17 US disclosed
US-20090105211-A1 INHIBITORS OF HEDGEHOG PATHWAY EXELIXIS, INC. (US) 2009-04-23 US disclosed
US-20090105211-A1 INHIBITORS OF HEDGEHOG PATHWAY EXELIXIS, INC. (US) 2009-04-23 US disclosed
WO-2008112913-A1 INHIBITORS OF THE HEDGEHOG PATHWAY EXELIXIS, INC. (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105211-A1 INHIBITORS OF HEDGEHOG PATHWAY SHH, GLI1, SMO TDP1 4631/4885L3MBTL1 2668/4885POLB 4439/4885
US-20120245139-A1 INHIBITORS OF THE HEDGEHOG PATHWAY SHH, GLI1, SMO TDP1 4589/4885L3MBTL1 2622/4885POLB 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.